31P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia.
(1)H MRSI in vivo is increasingly being used to diagnose prostate cancer noninvasively by measurement of the resonance from choline-containing phospholipid metabolites. Although (31) P NMR in vivo or in vitro is potentially an excellent method for probing the phospholipid metabolites prominent in prostate cancer, it has been little used recently. Here, we report an in vitro (31)P NMR comparison of prostate cancer and benign prostatic hyperplasia, focusing on the levels of the major phospholipid metabolites. Unlike phosphocholine and glycerophosphocholine, phosphoethanolamine and glycerophosphoethanolamine (and their ratio) were significantly different between cancer and benign prostatic hyperplasia. The high level of phosphoethanolamine+glycerophosphoethanolamine relative to phosphocholine+glycerophosphocholine suggests that the former may be significant contributors to the "total choline" resonance observed by (1)H MRSI in vivo.
Komoroski
Richard A
RA
Center for Imaging Research and Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio 45267-0583, USA. richard.komoroski@uc.edu
Holder
John C
JC
Pappas
Alex A
AA
Finkbeiner
Alex E
AE
D014408:Biomarkers, Tumor / Q000032:analysis*; D006801:Humans; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D008297:Male; D010743:Phospholipids / Q000032:analysis*; D010759:Phosphorus Isotopes; D011470:Prostatic Hyperplasia / Q000175:diagnosis* / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000378:metabolism*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D010743:Phospholipids; D010759:Phosphorus Isotopes